Last Updated: May 10, 2026

Details for Patent: 11,596,634


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,596,634 protect, and when does it expire?

Patent 11,596,634 protects SUBVENITE and is included in one NDA.

Summary for Patent: 11,596,634
Title:Lamotrigine oral liquid suspension and use thereof
Abstract:The present invention relates to an oral liquid suspension that includes lamotrigine and methods of medical treatment that include administering the oral liquid suspension. The oral liquid suspension has desirable physicochemical properties and technical attributes. The oral liquid suspension is useful in patients having difficulties in swallowing tablets and provide medical practitioners with additional options for dose titration.
Inventor(s):Paul Sudhakar, Scott Boyer
Assignee: OWP Pharmaceuticals Inc
Application Number:US15/929,929
Patent Claim Types:
see list of patent claims
Use; Formulation; Device; Dosage form;

Drugs Protected by US Patent 11,596,634

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Owp Pharms SUBVENITE lamotrigine SUSPENSION;ORAL 218879-001 Sep 16, 2025 RX Yes Yes 11,596,634 ⤷  Start Trial ADJUNCTIVE THERAPY FOR PARTIAL-ONSET, PRIMARY GENERALIZED TONIC-CLONIC (PGTC), OR LENNOX-GASTAUT SEIZURES IN PATIENTS 2 YEARS AND OLDER ⤷  Start Trial
Owp Pharms SUBVENITE lamotrigine SUSPENSION;ORAL 218879-001 Sep 16, 2025 RX Yes Yes 11,596,634 ⤷  Start Trial MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY MOOD EPISODES ⤷  Start Trial
Owp Pharms SUBVENITE lamotrigine SUSPENSION;ORAL 218879-001 Sep 16, 2025 RX Yes Yes 11,596,634 ⤷  Start Trial CONVERSION TO MONOTHERAPY FOR PARTIAL-ONSET SEIZURES IN PATIENTS 16 YEARS AND OLDER ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.